Importantly, IL-18 has also been implicated in activating ILC2 responses in chronic myeloid leukemia and prostate cancer (9, 15) promoting immune suppression and tumor progression, raising the possibility that similar mechanisms may be involved also in thymic carcinoma. The gene discussed is IL18; the disease is prostate cancer.